Haic+tae + tislelizumab + surufatinib

1 treatment and condition followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Haic+tae + tislelizumab + surufatinib
Treatment and conditionWhere it standsTrials
Haic+tae + tislelizumab + surufatinib for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1